Crinetics Pharmaceuticals Q4 2025 Earnings Call Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 27 2026
0mins
Should l Buy CRNX?
Source: seekingalpha
- Successful Product Launch: Crinetics' first commercial product, PALSONIFY, was successfully launched, with CEO Struthers noting over 200 enrollment forms received in Q4, indicating strong market demand and positioning the drug as the preferred treatment for acromegaly, thereby solidifying the company's market position in endocrinology.
- Strong Financial Performance: In Q4 2025, Crinetics reported total net revenue of $6.2 million, with $5.4 million from PALSONIFY's U.S. commercial sales and $0.8 million from a licensing agreement with a Japanese partner, showcasing a solid start in its commercialization efforts.
- Ongoing R&D Investment: Although R&D expenses for 2025 were $85.1 million, down from $90.5 million in Q3, the company plans to increase operating expenses in 2026 to support new clinical trials and PALSONIFY's commercialization, reflecting confidence in future growth.
- Healthy Cash Flow Position: By the end of 2025, Crinetics had over $1 billion in cash and cash equivalents, and with the January 2026 public offering, total funds are expected to reach approximately $1.4 billion, ensuring sufficient capital to fund operations into 2030 and supporting long-term growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRNX
Wall Street analysts forecast CRNX stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 39.020
Low
67.00
Averages
89.40
High
105.00
Current: 39.020
Low
67.00
Averages
89.40
High
105.00
About CRNX
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Neutrolis Appoints New Chief Business & Strategy Officer
- Leadership Change: Neutrolis has appointed Caren Deardorf as Chief Business & Strategy Officer, tasked with advancing NTR-1011 for autoimmune diseases, indicating the company's strategic focus on clinical pipeline progression.
- Extensive Industry Experience: Deardorf brings over 30 years of leadership experience in biopharma, having held executive roles at Editas Medicine and Biogen, where she successfully led multiple global product launches, enhancing Neutrolis's market competitiveness.
- Strategic Vision and Execution: Neutrolis CEO Anthony Aiudi praised Deardorf's commercial acuity and strategic vision, emphasizing that her leadership will be crucial for advancing the company's pipeline and expanding strategic partnerships, signaling future growth potential.
- Innovative Therapeutic Approach: Neutrolis focuses on developing rapid-acting, non-immunosuppressive therapies targeting Neutrophil Extracellular Traps (NETs), and Deardorf's addition is expected to accelerate the clinical application of this innovative therapy, addressing urgent needs in autoimmune disease patients.
See More
Neutrolis Appoints New Chief Business Officer
- Leadership Change: Neutrolis has appointed Caren Deardorf as Chief Business & Strategy Officer, tasked with advancing NTR-1011 for autoimmune diseases, marking a significant strategic shift in the company's clinical pipeline development.
- Extensive Industry Experience: With over 30 years in biopharma leadership, Deardorf previously served as Chief Commercial Officer at Editas Medicine, successfully launching multiple global products, which is expected to provide Neutrolis with valuable market insights and strategic direction.
- Clear Strategic Goals: Deardorf expressed her commitment to creating shareholder value and addressing unmet patient needs, aligning closely with Neutrolis's mission and indicating potential breakthroughs in autoimmune disease treatment.
- Innovative Therapeutic Approach: Neutrolis focuses on developing rapid-acting, non-immunosuppressive therapies targeting Neutrophil Extracellular Traps, and Deardorf's leadership is anticipated to accelerate the clinical advancement of this novel therapy, enhancing the company's competitiveness in the biopharma market.
See More
Crinetics (CRNX.US) Officer Plans to Sell $3.27 Million in Common Stock via Form 144
Stock Sale Announcement: Jeff Knight plans to sell 85,163 shares of Crinetics (CRNX.US) common stock on April 8, with an estimated market value of around $3.27 million.
Reduction in Shareholding: Since March 16, 2026, Jeff Knight has reduced his shareholding in Crinetics by 9,911 shares, valued at approximately $370.41K.
See More
Crinetics Pharmaceuticals Director Sells Shares
- Share Sale Details: On March 12, 2026, Crinetics Pharmaceuticals director Rogerio Vivaldi Coelho sold 5,000 shares for approximately $180,761, reducing his direct ownership to 16,300 shares, indicating a strategic liquidity move rather than a lack of confidence in the company.
- Market Reaction Analysis: The sale represented 23.47% of Coelho's direct holdings and occurred amidst a 4% decline in share price, suggesting that this transaction was more about liquidity needs than signaling positive business outlook.
- Financial Performance Overview: Crinetics reported $7.7 million in revenue for 2025, largely driven by the successful launch of its lead drug Palsonify, which generated $5.4 million in its first quarter, highlighting the company's potential in early commercialization.
- R&D Spending and Market Expansion: Despite R&D expenditures exceeding $330 million, Crinetics is expanding internationally, recently submitting a marketing application for Palsonify in Brazil, which could further enhance growth prospects moving forward.
See More
Crinetics Pharmaceuticals Director Sells 5,000 Shares
- Sale Overview: Rogerio Vivaldi Coelho, a director at Crinetics Pharmaceuticals, sold 5,000 shares of common stock on March 12, 2026, for approximately $181,000, reducing his direct holdings to 16,300 shares valued at around $595,000 post-transaction.
- Transaction Context: This sale accounted for 23.47% of Coelho's direct ownership, marking his first public open-market sale, executed automatically under a Rule 10b5-1 trading plan adopted on December 11, 2025, indicating a non-discretionary liquidity management strategy.
- Market Reaction and Valuation: The shares were sold at a weighted average price of about $36.15, closely aligned with the market close of $36.51 on March 12, 2026, suggesting that the transaction did not significantly impact market pricing, reflecting stability in the stock.
- Company Growth Prospects: Crinetics Pharmaceuticals generated $7.7 million in revenue for 2025, primarily driven by the successful launch of its lead drug, Palsonify, and despite R&D expenses exceeding $330 million, the company’s international expansion and $1.4 billion in cash post-offering position it well for future growth.
See More
Crinetics Pharmaceuticals COO Resignation and Future Plans
- Executive Resignation: Crinetics Pharmaceuticals' Chief Development and Operating Officer Jeff Knight will resign effective April 10, 2026, with his responsibilities and team reassigned to other executives, potentially impacting operational efficiency and decision-making processes.
- Financial Planning: The company outlines a $600 million to $650 million operating expense plan for 2026, aimed at supporting the accelerated launch of PALSONIFY, reflecting its commitment to the market potential of new products.
- Market Environment: Amid disruptions in the Middle East, Wall Street's focus on oversold mid-cap healthcare stocks has increased, placing Crinetics under greater market pressure and investor scrutiny.
- Investor Engagement: Crinetics presented at the TD Cowen 46th Annual Health Care Conference, indicating its proactive approach in communicating future strategies and financial health to investors.
See More
Neutrolis Appoints New Chief Business & Strategy Officer
- Leadership Change: Neutrolis has appointed Caren Deardorf as Chief Business & Strategy Officer, tasked with advancing NTR-1011 for autoimmune diseases, indicating the company's strategic focus on clinical pipeline progression.
- Extensive Industry Experience: Deardorf brings over 30 years of leadership experience in biopharma, having held executive roles at Editas Medicine and Biogen, where she successfully led multiple global product launches, enhancing Neutrolis's market competitiveness.
- Strategic Vision and Execution: Neutrolis CEO Anthony Aiudi praised Deardorf's commercial acuity and strategic vision, emphasizing that her leadership will be crucial for advancing the company's pipeline and expanding strategic partnerships, signaling future growth potential.
- Innovative Therapeutic Approach: Neutrolis focuses on developing rapid-acting, non-immunosuppressive therapies targeting Neutrophil Extracellular Traps (NETs), and Deardorf's addition is expected to accelerate the clinical application of this innovative therapy, addressing urgent needs in autoimmune disease patients.
See More
Neutrolis Appoints New Chief Business Officer
- Leadership Change: Neutrolis has appointed Caren Deardorf as Chief Business & Strategy Officer, tasked with advancing NTR-1011 for autoimmune diseases, marking a significant strategic shift in the company's clinical pipeline development.
- Extensive Industry Experience: With over 30 years in biopharma leadership, Deardorf previously served as Chief Commercial Officer at Editas Medicine, successfully launching multiple global products, which is expected to provide Neutrolis with valuable market insights and strategic direction.
- Clear Strategic Goals: Deardorf expressed her commitment to creating shareholder value and addressing unmet patient needs, aligning closely with Neutrolis's mission and indicating potential breakthroughs in autoimmune disease treatment.
- Innovative Therapeutic Approach: Neutrolis focuses on developing rapid-acting, non-immunosuppressive therapies targeting Neutrophil Extracellular Traps, and Deardorf's leadership is anticipated to accelerate the clinical advancement of this novel therapy, enhancing the company's competitiveness in the biopharma market.
See More
Crinetics (CRNX.US) Officer Plans to Sell $3.27 Million in Common Stock via Form 144
Stock Sale Announcement: Jeff Knight plans to sell 85,163 shares of Crinetics (CRNX.US) common stock on April 8, with an estimated market value of around $3.27 million.
Reduction in Shareholding: Since March 16, 2026, Jeff Knight has reduced his shareholding in Crinetics by 9,911 shares, valued at approximately $370.41K.
See More
Crinetics Pharmaceuticals Director Sells Shares
- Share Sale Details: On March 12, 2026, Crinetics Pharmaceuticals director Rogerio Vivaldi Coelho sold 5,000 shares for approximately $180,761, reducing his direct ownership to 16,300 shares, indicating a strategic liquidity move rather than a lack of confidence in the company.
- Market Reaction Analysis: The sale represented 23.47% of Coelho's direct holdings and occurred amidst a 4% decline in share price, suggesting that this transaction was more about liquidity needs than signaling positive business outlook.
- Financial Performance Overview: Crinetics reported $7.7 million in revenue for 2025, largely driven by the successful launch of its lead drug Palsonify, which generated $5.4 million in its first quarter, highlighting the company's potential in early commercialization.
- R&D Spending and Market Expansion: Despite R&D expenditures exceeding $330 million, Crinetics is expanding internationally, recently submitting a marketing application for Palsonify in Brazil, which could further enhance growth prospects moving forward.
See More
Crinetics Pharmaceuticals Director Sells 5,000 Shares
- Sale Overview: Rogerio Vivaldi Coelho, a director at Crinetics Pharmaceuticals, sold 5,000 shares of common stock on March 12, 2026, for approximately $181,000, reducing his direct holdings to 16,300 shares valued at around $595,000 post-transaction.
- Transaction Context: This sale accounted for 23.47% of Coelho's direct ownership, marking his first public open-market sale, executed automatically under a Rule 10b5-1 trading plan adopted on December 11, 2025, indicating a non-discretionary liquidity management strategy.
- Market Reaction and Valuation: The shares were sold at a weighted average price of about $36.15, closely aligned with the market close of $36.51 on March 12, 2026, suggesting that the transaction did not significantly impact market pricing, reflecting stability in the stock.
- Company Growth Prospects: Crinetics Pharmaceuticals generated $7.7 million in revenue for 2025, primarily driven by the successful launch of its lead drug, Palsonify, and despite R&D expenses exceeding $330 million, the company’s international expansion and $1.4 billion in cash post-offering position it well for future growth.
See More
Crinetics Pharmaceuticals COO Resignation and Future Plans
- Executive Resignation: Crinetics Pharmaceuticals' Chief Development and Operating Officer Jeff Knight will resign effective April 10, 2026, with his responsibilities and team reassigned to other executives, potentially impacting operational efficiency and decision-making processes.
- Financial Planning: The company outlines a $600 million to $650 million operating expense plan for 2026, aimed at supporting the accelerated launch of PALSONIFY, reflecting its commitment to the market potential of new products.
- Market Environment: Amid disruptions in the Middle East, Wall Street's focus on oversold mid-cap healthcare stocks has increased, placing Crinetics under greater market pressure and investor scrutiny.
- Investor Engagement: Crinetics presented at the TD Cowen 46th Annual Health Care Conference, indicating its proactive approach in communicating future strategies and financial health to investors.
See More
